...
首页> 外文期刊>Pediatric drugs >Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children
【24h】

Drug Dose Selection in Pediatric Obesity: Available Information for the Most Commonly Prescribed Drugs to Children

机译:儿科肥胖药物剂量选择:为儿童提供最常用的药物的可用信息

获取原文
获取原文并翻译 | 示例
           

摘要

Obesity rates continue to rise in children, and little guidance exists regarding the need for adjustment away from total body weight-based doses for those prescribing drugs to this population of children. A majority of drugs prescribed to children with obesity result in either sub-therapeutic or supra-therapeutic concentrations, placing these children at risk for treatment failure and drug toxicities. In this review, we highlight available obesity-specific pharmacokinetic and dosing information for the most frequently prescribed drugs to children in the inpatient and outpatient clinical settings. We also comment on available dosing recommendations for drugs prescribed to treat common pediatric obesity-related comorbidities. This review highlights that there is no safe or proven 'rule of thumb,' for dosing drugs for children with obesity, and a striking lack of pharmacokinetic data to support the creation of dosing guidelines for children with obesity for the most commonly prescribed drugs. It is important that those prescribing for children with obesity are aware of these gaps in knowledge and of potential drug treatment failure or adverse events related to drug toxicity as a result of these knowledge gaps. Until more data are available, we recommend close monitoring of drug response and adverse events in children with obesity receiving commonly prescribed drugs.
机译:儿童的肥胖率继续上升,有关对这些儿童人群的那些规定的毒品的含量调节需要对众多体重的剂量进行调整的必要性。对于具有肥胖的儿童的大多数药物导致亚治疗性或同上治疗浓度,将这些儿童放置在治疗失败和药物毒性的风险。在这篇综述中,我们突出了适用于住院患者和门诊临床环境中最常规定的药物的可用肥胖特异性药代动力学和给药信息。我们还评论了用于治疗常见儿科肥胖相关的合并症的药物的可用剂量推荐。这篇综述强调,对于用肥胖儿童的药物,没有安全或证明的拇指规则,以及缺乏药代动力学数据,以支持为最常见的药物肥胖的儿童创造给药指导性。重要的是,由于这些知识差距,对具有肥胖的儿童的那些规定的人意识到了知识中的这些差距以及与药物毒性有关的不良事件。直到有更多数据可用,我们建议在接受普通规定药物的肥胖症中密切监测药物反应和不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号